Christopher Gillies

Dr. Christopher Gillies


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBenjamin B. Sun
Benjamin B. Sun
JCJoshua Chiou
Joshua Chiou
MTMatthew Traylor
Matthew Traylor
CBChristian Benner
Christian Benner
YHYi-Hsiang Hsu
Yi-Hsiang Hsu
CWChristopher D. Whelan
Christopher D. Whelan
The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the UK Biobank (UKB) and thirteen biopharmaceutical companies characterising the plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from the first phase of UKB-PPP, including protein quantitative trait loci (pQTL) mapping of 1,463 proteins that identifies 10,248 primary genetic associations, of which 85% are newly discovered. We also identify independent secondary associations in 92% of cis and 29% of trans loci, expanding the catalogue of genetic instruments for downstream analyses. The study provides an updated characterisation of the genetic architecture of the plasma proteome, leveraging population-scale proteomics to provide novel, extensive insights into trans pQTLs across multiple biological domains. We highlight genetic influences on ligand-receptor interactions and pathway perturbations across a diverse collection of cytokines and complement proteins, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug target discovery by extending the genetic proxied effect of PCSK9 levels on lipid concentrations, cardio- and cerebro-vascular diseases, and additionally disentangle specific genes and proteins perturbed at COVID-19 susceptibility loci. This public-private partnership provides the scientific community with an open-access proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries and accelerate the development of novel biomarkers and therapeutics.

21 April 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
BCBrandon C Cummings
Brandon C Cummings
SASardar Ansari
Sardar Ansari
JMJonathan R Motyka
Jonathan R Motyka
GWGuan Wang
Guan Wang
RJRichard P Medlin Jr
Richard P Medlin Jr
CGChristopher Gillies
Christopher Gillies
Background: COVID-19 has led to an unprecedented strain on health care facilities across the United States. Accurately identifying patients at an increased risk of deterioration may help hospitals manage their resources while improving the quality of patient care. Here, we present the results of an analytical model, Predicting Intensive Care Transfers and Other Unforeseen Events (PICTURE), to identify patients at high risk for imminent intensive care unit transfer, respiratory failure, or death, with the intention to improve the prediction of deterioration due to COVID-19. Objective: This study aims to validate the PICTURE model’s ability to predict unexpected deterioration in general ward and COVID-19 patients, and to compare its performance with the Epic Deterioration Index (EDI), an existing model that has recently been assessed for use in patients with COVID-19. Methods: The PICTURE model was trained and validated on a cohort of hospitalized non–COVID-19 patients using electronic health record data from 2014 to 2018. It was then applied to two holdout test sets: non–COVID-19 patients from 2019 and patients testing positive for COVID-19 in 2020. PICTURE results were aligned to EDI and NEWS scores for head-to-head comparison via area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve. We compared the models’ ability to predict an adverse event (defined as intensive care unit transfer, mechanical ventilation use, or death). Shapley values were used to provide explanations for PICTURE predictions. Results: In non–COVID-19 general ward patients, PICTURE achieved an AUROC of 0.819 (95% CI 0.805-0.834) per observation, compared to the EDI’s AUROC of 0.763 (95% CI 0.746-0.781; n=21,740; P<.001). In patients testing positive for COVID-19, PICTURE again outperformed the EDI with an AUROC of 0.849 (95% CI 0.820-0.878) compared to the EDI’s AUROC of 0.803 (95% CI 0.772-0.838; n=607; P<.001). The most important variables influencing PICTURE predictions in the COVID-19 cohort were a rapid respiratory rate, a high level of oxygen support, low oxygen saturation, and impaired mental status (Glasgow Coma Scale). Conclusions: The PICTURE model is more accurate in predicting adverse patient outcomes for both general ward patients and COVID-19 positive patients in our cohorts compared to the EDI. The ability to consistently anticipate these events may be especially valuable when considering potential incipient waves of COVID-19 infections. The generalizability of the model will require testing in other health care systems for validation.

1 October 2020 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
CGChristopher Gillies
Christopher Gillies
DTDaniel F. Taylor
Daniel F. Taylor
BCBrandon C. Cummings
Brandon C. Cummings
SASardar Ansari
Sardar Ansari
FIFadi Islim
Fadi Islim
KWKevin R. Ward
Kevin R. Ward

6 August 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
CGChristopher Gillies
Christopher Gillies
TJTheodore Jennaro
Theodore Jennaro
MPMichael Puskarich
Michael Puskarich
RSRuchi Sharma
Ruchi Sharma
KWKevin R. Ward
Kevin R. Ward
KSKathleen Stringer
Kathleen Stringer
To ensure scientific reproducibility of metabolomics data, alternative statistical methods are needed. A paradigm shift away from the p-value toward an embracement of uncertainty and interval estimation of a metabolite’s true effect size may lead to improved study design and greater reproducibility. Multilevel Bayesian models are one approach that offer the added opportunity of incorporating imputed value uncertainty when missing data are present. We designed simulations of metabolomics data to compare multilevel Bayesian models to standard logistic regression with corrections for multiple hypothesis testing. Our simulations altered the sample size and the fraction of significant metabolites truly different between two outcome groups. We then introduced missingness to further assess model performance. Across simulations, the multilevel Bayesian approach more accurately estimated the effect size of metabolites that were significantly different between groups. Bayesian models also had greater power and mitigated the false discovery rate. In the presence of increased missing data, Bayesian models were able to accurately impute the true concentration and incorporating the uncertainty of these estimates improved overall prediction. In summary, our simulations demonstrate that a multilevel Bayesian approach accurately quantifies the estimated effect size of metabolite predictors in regression modeling, particularly in the presence of missing data.

8 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
TJTyler Joseph
Tyler Joseph
JMJoelle Mbatchou
Joelle Mbatchou
AGArkopravo Ghosh
Arkopravo Ghosh
AMAnthony Marcketta
Anthony Marcketta
CGChristopher Gillies
Christopher Gillies
JMJonathan Marchini
Jonathan Marchini
Meta-analysis of gene-based tests using single variant summary statistics is a powerful strategy for associating genes with disease. However, current approaches require sharing the covariance matrix between variants for each study and trait of interest. For large-scale studies with many phenotypes, these matrices can be cumbersome to calculate, store, and share. To address this challenge, we present REMETA, an efficient tool for meta-analysis of gene-based tests. REMETA uses a single sparse covariance reference file per study that is rescaled for each phenotype using single variant summary statistics. We develop methods to apply REMETA to binary traits with case-control imbalance, and estimate allele frequencies, genotype counts and effect sizes of burden tests. We demonstrate the performance and advantages of our approach via meta-analysis of 5 traits in 469,376 samples in UK Biobank. The open-source REMETA software tools and framework will facilitate meta-analysis across large scale exome sequencing studies from diverse studies that cannot easily be brought together.

10 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BCBrandon C. Cummings
Brandon C. Cummings
SASardar Ansari
Sardar Ansari
JMJonathan R. Motyka
Jonathan R. Motyka
GWGuan Wang
Guan Wang
RMRichard P. Medlin
Richard P. Medlin
CGChristopher Gillies
Christopher Gillies
Introduction: The 2019 coronavirus (COVID-19) has led to unprecedented strain on healthcare facilities across the United States. Accurately identifying patients at an increased risk of deterioration may help hospitals manage their resources while improving the quality of patient care. Here we present the results of an analytical model, PICTURE ( P redicting I ntensive C are T ransfers and Other U nfo R eseen E vents), to identify patients at a high risk for imminent intensive care unit (ICU) transfer, respiratory failure, or death with the intention to improve prediction of deterioration due to COVID-19. We compare PICTURE to the Epic Deterioration Index (EDI), a widespread system which has recently been assessed for use to triage COVID-19 patients. Methods: The PICTURE model was trained and validated on a cohort of hospitalized non-COVID-19 patients using electronic health record data from 2014-2018. It was then applied to two hold-out test sets: non-COVID-19 patients from 2019 and patients testing positive for COVID-19 in 2020. PICTURE results were aligned to the EDI for head-to-head comparison via Area Under the Receiver Operator Curve (AUROC) and Area Under the Precision Recall Curve (AUPRC). We compared the models’ ability to predict an adverse event (defined as ICU transfer, mechanical ventilation use, or death) at two levels of granularity: (1) maximum score across an encounter with a minimum lead time before the first adverse event and (2) predictions at every observation with instances in the last 24 hours before the adverse event labeled as positive. PICTURE and the EDI were also compared on the encounter level using different lead times extending out to 24 hours. Shapley values were used to provide explanations for PICTURE predictions. Results: PICTURE successfully delineated between high- and low-risk patients and consistently outperformed the EDI in both of our cohorts. In non-COVID-19 patients, PICTURE achieved an AUROC (95% CI) of 0.819 (0.805 - 0.834) and AUPRC of 0.109 (0.089 - 0.125) on the observation level, compared to the EDI AUROC of 0.762 (0.746 - 0.780) and AUPRC of 0.077 (0.062 - 0.090). On COVID-19 positive patients, PICTURE achieved an AUROC of 0.828 (0.794 - 0.869) and AUPRC of 0.160 (0.089 - 0.199), while the EDI scored an AUROC of 0.792 (0.754 - 0.835) and AUPRC of 0.131 (0.092 - 0.159). The most important variables influencing PICTURE predictions in the COVID-19 cohort were a rapid respiratory rate, a high level of oxygen support, low oxygen saturation, and impaired mental status (Glasgow coma score). Conclusion: The PICTURE model is more accurate in predicting adverse patient outcomes for both general ward patients and COVID-19 positive patients in our cohorts compared to the EDI. The ability to consistently anticipate these events may be especially valuable when considering a potential incipient second wave of COVID-19 infections. PICTURE also has the ability to explain individual predictions to clinicians by ranking the most important features for a prediction. The generalizability of the model will require testing in other health care systems for validation.